Jorge Plutzky

Q: What Schools Are Affiliated With Jorge Plutzky

Jorge Plutzky is affiliated with the following schools: University of Melbourne, University of Toronto, Rush University, Harvard University

Jorge Plutzky's AcademicInfluence.com Rankings

Jorge Plutzky

Medical

#2896

World Rank

#3340

Historical Rank

Cardiology

#284

World Rank

#290

Historical Rank

medical Degrees

Jorge Plutzky

Philosophy

#8299

World Rank

#11652

Historical Rank

Logic

#5334

World Rank

#6725

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Jorge Plutzky's Degrees

Doctorate Medicine Harvard University

Why Is Jorge Plutzky Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jorge Plutzky's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. (1998) (1937)
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006) (946)
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. (1998) (630)
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2007) (587)
PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells (1999) (568)
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies (2008) (525)
Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro (1998) (516)
NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. (2014) (480)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. (2008) (473)
The pathologic continuum of diabetic vascular disease. (2009) (420)
Discontinuation of Statins in Routine Care Settings (2013) (392)
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). (2006) (387)
PPAR Activators as Antiinflammatory Mediators in Human T Lymphocytes: Implications for Atherosclerosis and Transplantation-Associated Arteriosclerosis (2002) (370)
PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease (1999) (361)
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. (1992) (342)
BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure (2013) (333)
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. (2007) (325)
Retinaldehyde represses adipogenesis and diet-induced obesity (2007) (303)
Inflammatory pathways in atherosclerosis and acute coronary syndromes. (2001) (288)
Isolation of a src homology 2-containing tyrosine phosphatase. (1992) (282)
Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells1 (2000) (279)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients (2008) (261)
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase (2003) (253)
Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. (1998) (245)
Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR–RXR complex (2008) (210)
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. (1999) (196)
Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions (2014) (192)
Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. (2015) (190)
Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue (2012) (189)
The transcription factor cyclic AMP–responsive element–binding protein H regulates triglyceride metabolism (2011) (189)
PPARα in atherosclerosis and inflammation (2007) (171)
Evolution and organization of the human protein C gene. (1986) (170)
Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders (2016) (166)
PPAR&agr; Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes (2001) (164)
Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. (2002) (159)
Residual macrovascular risk in 2013: what have we learned? (2014) (157)
The vascular biology of atherosclerosis. (2003) (156)
Discontinuation of Statin in Routine Care Settings: A Cohort Study (2013) (154)
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? (2007) (149)
Diabetic macrovascular disease: the glucose paradox? (2002) (144)
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. (1999) (144)
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. (2008) (142)
Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes (2006) (141)
The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. (1985) (137)
Deletion of the α-Arrestin Protein Txnip in Mice Promotes Adiposity and Adipogenesis While Preserving Insulin Sensitivity (2010) (136)
Asymmetric cleavage of beta-carotene yields a transcriptional repressor of retinoid X receptor and peroxisome proliferator-activated receptor responses. (2007) (130)
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. (2017) (129)
Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway (2012) (123)
Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists (2007) (117)
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. (2006) (116)
A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid utilization (2013) (115)
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. (2008) (113)
Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction (2003) (113)
The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance (2011) (107)
Atherosclerotic plaque rupture: emerging insights and opportunities. (1999) (100)
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. (2000) (99)
PPARs as Therapeutic Targets: Reverse Cardiology? (2003) (96)
Leukotriene E4 Activates Peroxisome Proliferator-activated Receptor γ and Induces Prostaglandin D2 Generation by Human Mast Cells* (2008) (95)
Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice (2011) (93)
Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. (2002) (91)
Epigenetic Changes in Diabetes and Cardiovascular Risk. (2016) (90)
PPARalpha in atherosclerosis and inflammation. (2007) (90)
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. (2020) (90)
Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms (2000) (87)
Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. (2012) (86)
High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR&agr;: A Candidate Mechanism for High-Density Lipoprotein–Mediated Repression of Leukocyte Adhesion (2006) (85)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering (1999) (83)
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. (2014) (79)
The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. (2003) (78)
VLDL hydrolysis by LPL activates PPAR-α through generation of unbound fatty acids (2010) (67)
Dual Roles for Lipolysis and Oxidation in Peroxisome Proliferation-Activator Receptor Responses to Electronegative Low Density Lipoprotein* (2003) (67)
The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. (2012) (66)
Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk? (2001) (63)
Emerging concepts in metabolic abnormalities associated with coronary artery disease (2000) (61)
Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. (2007) (61)
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. (2020) (61)
Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes (2017) (60)
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. (2019) (60)
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. (2012) (59)
Retinoid Metabolism and Diabetes Mellitus (2012) (59)
Peroxisome proliferator-activated receptors in endothelial cell biology (2001) (58)
BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. (2020) (57)
Pioglitazone Suppresses Inflammation In Vivo in Murine Carotid Atherosclerosis: Novel Detection by Dual-Target Fluorescence Molecular Imaging (2010) (56)
Insights into the Molecular Mechanisms of the Anti-Atherogenic Actions of Flavonoids in Normal and Obese Mice (2011) (54)
BET bromodomain proteins regulate enhancer function during adipogenesis (2018) (54)
Retinoid metabolism and its effects on the vasculature. (2012) (50)
Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). (1992) (47)
Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. (2016) (46)
Macrovascular effects and safety issues of therapies for type 2 diabetes. (2011) (43)
Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study (2016) (43)
Inflammation in Atherosclerosis and Diabetes Mellitus (2004) (41)
Endothelial Lipase Is a Critical Determinant of High-Density Lipoprotein–Stimulated Sphingosine 1-Phosphate–Dependent Signaling in Vascular Endothelium (2013) (41)
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. (2012) (40)
Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. (2015) (38)
Enhanced fatty acid flux triggered by adiponectin overexpression. (2012) (37)
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. (2018) (37)
Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. (2020) (35)
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. (2010) (34)
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. (2020) (34)
Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. (2011) (33)
Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. (2003) (31)
Differential role of an NF-κB transcriptional response element in endothelial versus intimal cell VCAM-1 expression. (2015) (30)
Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions (2002) (29)
Statins for stroke: the second story? (2001) (29)
Medicine. PPARs as therapeutic targets: reverse cardiology? (2003) (27)
Deficiency of Retinaldehyde Dehydrogenase 1 Induces BMP2 and Increases Bone Mass In Vivo (2013) (26)
Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. (2020) (25)
Lipolytic PPAR activation: new insights into the intersection of triglycerides and inflammation? (2004) (25)
Oxidative stress and peroxisome proliferator-activated receptors: reversing the curse? (2004) (25)
Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. (2009) (25)
The incretin axis in cardiovascular disease. (2011) (24)
Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry (2019) (24)
VLDL Hydrolysis by Hepatic Lipase Regulates PPARδ Transcriptional Responses (2011) (24)
Peroxisome proliferator-activated receptors (2002) (24)
PPARa Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells (1999) (22)
Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. (2005) (22)
Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. (2012) (20)
Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction: The Mass General Brigham YOUNG-MI Registry. (2021) (19)
Discontinuation of Statins in Routine Care Settings (2013) (19)
Liver X receptor activation and high-density lipoprotein biology: a reversal of fortune? (2005) (17)
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials (2018) (17)
NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood? (2012) (17)
Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities (2003) (17)
Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects (2019) (16)
A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. (2019) (16)
Expansion and contraction: the mighty, mighty fatty acid (2009) (14)
Secondary Prevention of Myocardial Infarction (1999) (14)
Extensive metabolic disorders are present in APC min tumorigenesis mice (2016) (14)
Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda (2018) (14)
Effect of lipid-lowering therapy on vasomotion and endothelial function (1999) (13)
Prediabetes mellitus and its links to atherosclerosis (2003) (13)
Lipids in RA: Is Less Not Necessarily More? (2018) (13)
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases (2021) (13)
The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation (2019) (12)
Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway (2012) (12)
Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice. (2016) (11)
Management of low levels of high-density lipoprotein-cholesterol. (2013) (11)
Liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure within 2 weeks in patients with type 2 diabetes (2009) (10)
Intact vitamin A transport is critical for cold-mediated adipose tissue browning and thermogenesis (2020) (10)
Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort. (2015) (10)
Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. (2016) (10)
Cardiovascular disease, chronic kidney disease, and type 2 diabetes mellitus: proceeding with caution at a dangerous intersection. (2008) (10)
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARα (2007) (10)
Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations (2021) (10)
Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration (2019) (9)
Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling (2017) (9)
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. (2023) (9)
Diabetes and the Cardiovascular System (2013) (9)
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page (2018) (8)
BRD2 regulation of sigma-2 receptor upon cholesterol deprivation (2020) (8)
Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity. (2014) (8)
On being a physician. (1990) (8)
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network. (2022) (8)
WEIGHT LOSS, BLOOD PRESSURE, PULSE AND CIRCADIAN PATTERNS WITH NALTREXONE SUSTAINED-RELEASE/BUPROPION SUSTAINED-RELEASE COMBINATION THERAPY FOR OBESITY (2011) (6)
Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects (2018) (6)
A cardiologist's perspective on cardiometabolic risk. (2007) (5)
Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins (2021) (5)
Peroxisome Proliferator-Activated Receptor-g Activators Inhibit IFN- g-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells (2000) (5)
Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. (2020) (5)
Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation (2020) (5)
Leukotriene E 4 Activates Peroxisome Proliferator-activated Receptor and Induces Prostaglandin D 2 Generation by (2008) (5)
Predictors of a successful statin reattempt after an adverse reaction. (2018) (5)
Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes (2007) (5)
The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. (2011) (5)
Abstract 818: Plasminogen Activator Inhibitor-1 is Reduced by the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide When Used in the Treatment of Type 2 Diabetes (2009) (4)
A REMOTE LIPID MANAGEMENT PROGRAM IMPROVES APPROPRIATE STATIN USE AND CHOLESTEROL LEVELS ACROSS A WIDE POPULATION OF HIGH CARDIOVASCULAR RISK PATIENTS (2018) (4)
To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa (2020) (4)
Short Communication Macrophages in Human Atheroma Contain PPARg Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor g (PPARg) Expression and Reduction of MMP-9 Activity through PPARg Activation in Mononuclear Phagocytes in Vitro (1998) (3)
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2022) (3)
Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. (2014) (3)
and Migration in Human Vascular Smooth Muscle Cells Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression (1998) (3)
Impact of coronary artery calcium testing on patient management. (2021) (3)
Intersecting vectors of basic science research and clinical medicine: LOX-1? (2010) (3)
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. (2005) (3)
Exogenous and endogenous mechanisms of PPAR activation: implications for inflammation and atherosclerosis (2004) (3)
Shortwave infrared spatial frequency domain imaging for non-invasive measurement of tissue and blood optical properties (2022) (3)
Mig, and I-TAC in Human Endothelial Cells of the T Cell-Active CXC Chemokines IP-10, -Induced Expression g Activators Inhibit IFN-g Peroxisome Proliferator-Activated Receptor-Jorge (2000) (3)
Therapeutic Targets Activated Receptors as Transcriptional Nodal Points and − Peroxisome Proliferator (2007) (2)
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI (2018) (2)
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran (2022) (2)
BEMPEDOIC ACID 180 MG + EZETIMIBE 10 MG FIXED-DOSE COMBINATION VS EZETIMIBE ALONE OR PLACEBO IN PATIENTS WITH TYPE 2 DIABETES AND HYPERCHOLESTEROLEMIA (2020) (2)
Correction: Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling (2017) (2)
Pathophysiology of Atherosclerotic Heart Disease (2003) (2)
(Mis)interpreting studies on the adverse effects of statins (2014) (2)
Cold-mediated regulation of systemic retinol transport controls adipose tissue browning (2020) (1)
PPARs and Their Emerging Role in Vascular Biology, Inflammation, and Atherosclerosis (2005) (1)
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. (2023) (1)
Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes (2015) (1)
Population Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program. (2021) (1)
PPARg in the endothelium regulates metabolic responses to high-fat diet in mice (2018) (1)
Endothelial Biomedicine: Peroxisome Proliferator-Activated Receptors and the Endothelium (2007) (1)
Eff ects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis : a randomised , double-blind , placebo-controlled trial (2015) (1)
Abstract 15089: Specificity for Inflammatory Pathways and Myocardial Injury Associated With Coronary Microvascular Dysfunction in Rheumatoid Arthritis (2020) (1)
The endocannabinoid system and the regulation of energy metabolism (2006) (1)
Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. (2020) (1)
PPARα and Atherosclerosis (2002) (1)
LIPID ABNORMALITIES IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION (2017) (1)
Obesity and atherosclerotic vascular disease (2006) (1)
The Pleiotropic Effects of Statins : Fact or Fantasy ? (1)
PPARs: altering clinical responses in Type 2 diabetes and atherosclerosis. Introduction. (2004) (1)
BRD2 regulation of sigma-2 receptor expression upon cytosolic cholesterol deprivation (2019) (1)
PREVALENCE AND TESTING OF LIPOPROTEIN(A) AMONG YOUNG ADULTS WITH MYOCARDIAL INFARCTION: THE PARTNERS YOUNG-MI REGISTRY (2020) (1)
PPAR and cardiovascular risk (2001) (1)
Evaluation of Mitral Valve Regurgitation : Implications for Percutaneous Mitral Valve Repair (1)
Emerging epigenetic maps in atherosclerosis. (2014) (0)
SCALING SECONDARY PREVENTION: MEDICATION OPTIMIZATION IN PATIENTS WITH ASCVD (2021) (0)
Abstract 17360: Four Factors Explain Most of the Gender Disparity in Statin Therapy (2014) (0)
Non-invasive Blood Lipid Monitoring using Shortwave Infrared Spatial Frequency Domain Imaging (SWIR SFDI) (2022) (0)
A REPORT BY THE CARDIOVASCULAR DIVISION OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS Cardiology Cardiology SCIENTIFIC UPDATE SCIENTIFIC UPDATE (2001) (0)
Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners (2018) (0)
WOMEN WHO EXPERIENCE MYOCARDIAL INFARCTION AT A YOUNG AGE HAVE WORSE SURVIVAL COMPARED WITH MEN (2017) (0)
Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARα Short title: Oxidized n-3 fatty acids inhibit inflammation via PPARα (2002) (0)
Abstract 582: A Novel PPAR{delta}-Hepatic Lipase Transcriptional Pathway (2007) (0)
interactions through activation of PPARalpha Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial (2010) (0)
Abstract 14109: Statin Eligibility Among Young Adults Prior to Myocardial Infarction (2017) (0)
Myocardial Infarction in the Younger Patient (1999) (0)
2218-PUB: Initiation of SGLT2 Inhibitors in Hospitalized Patients with CVD (2020) (0)
Abstract 1556: Retinaldehyde Inhibits Adipogenesis Through RXR and PPAR-gamma Repression (2006) (0)
as a Potential Mediator in Vascular Disease γ Type-1 Expression : PPAR Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor γ PPAR (1999) (0)
FOCUS ON RETEPLASE : A NEWLY APPROVED THIRD-GENERATION THROMBOLYTIC AGENT FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION (1997) (0)
A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia (2023) (0)
Abstract 12649: Remote, Integrated Algorithm-based CV Risk Management Program Improves Hypertension and LDL Control (2019) (0)
Abstract: 124 PATHOPHYSIOLOGY OF MET SYN AND RELATED CARDIOMETABOLIC RISK: WHAT'S NEW? (2009) (0)
Scattering and hemodynamic changes after a high-fat meal measured with SFDI (Conference Presentation) (2023) (0)
Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis (2022) (0)
Expression in Human Endothelial Cells Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 α PPAR (1999) (0)
Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance (2005) (0)
Abstract: 511 THE RXR-PPAR COMPLEX IN THE REGULATION OF ENERGY BALANCE (2009) (0)
Association of monocyte TNF α expression and serum inflammatory biomarkers with walking impairment in PAD (2014) (0)
Effect of a Peroxisome Proliferator–Activated Receptor- (cid:1) Agonist on Myocardial Blood Flow in Type 2 Diabetes (2005) (0)
The Veterans Administration-HDL Intervention Trial (VA-HIT) (1998) (0)
Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b-INHBA signaling axis. (2023) (0)
The Peroxisome Proliferator-Activated Receptor- (cid:1) Agonist Pioglitazone Represses Inﬂammation in a Peroxisome Proliferator-Activated Receptor- (cid:2) – Dependent Manner In Vitro and In Vivo in Mice (2008) (0)
Introduction (2004) (0)
patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic (2011) (0)
Abstract 17798: Statin Persistence After Reported Adverse Reactions and Patient Outcomes (2015) (0)
CARDIOVASCULAR BIOMARKERS OF LIPIDS AND SUBCLINICAL MYOCARDIAL INJURY DIVERGE DURING RHEUMATOID ARTHRITIS FLARE (2020) (0)
Abstract 3436: Endothelial PPAR{gamma} Regulates Lipid Metabolism And Adiposity After High Fat Feeding (2008) (0)
Abstract 16195: Socioeconomic Disadvantage is Associated With Higher Long-Term Cardiovascular Mortality Following Myocardial Infarction: The YOUNG-MI Registry (2020) (0)
Jorge Plutzky Emerging Epigenetic Maps in Atherosclerosis (0)
STATIN INTOLERANCE: A REMOTE, NAVIGATOR-LED STRATEGY TO COMBAT A COMMON CHALLENGE (2021) (0)
THE RELATIONSHIP BETWEEN ASCVD RISK, INFLAMMATION, AND CORONARY MICROVASCULAR DYSFUNCTION IN RHEUMATOID ARTHRITIS (2022) (0)
Abstract 5471: Peroxisome Proliferator-Activated Receptor-{gamma} Activation Reduces Inflammation in Atherosclerosis as Assessed by Serial In Vivo Fluorescence Molecular Imaging (2008) (0)
PPARs in Atherosclerosis (2008) (0)
Abstract 181: BET Bromodomain Inhibition Suppresses Endothelial Inflammation and Atherosclerosis (2013) (0)
Abstract 036: LDL-Cholesterol Lowering Among Young Adults Who Experience a First Myocardial Infarction (2017) (0)
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes (Acute Coronary Syndromes Through Renal Disease) and Future Directions (2006) (0)
Clinic-ready shortwave infrared spatial frequency domain imaging (SWIR SFDI) system for non-invasive monitoring of postprandial blood lipids (2022) (0)
Epigenetic Therapeutics for Cardiovascular Disease: Writing, Erasing, Reading, and Maybe Forgetting. (2020) (0)
Cardiovascular Disease Prevention (2012) (0)
Diabetes as a vascular disease. Dyslipidemia as a target. (2003) (0)
Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (0)
Abstract 12910: Use of Optimal Medical Therapy in Patients With Cardiovascular Disease Undergoing Cardiac Rehabilitation (2020) (0)
The Aging Aorta: Are We Only as Old as Our Endothelium? (2022) (0)
Edinburgh Research Explorer Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design (2020) (0)
PPARs in Diabetes and Cardiovascular Disease (2006) (0)
Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jorge Plutzky?

Jorge Plutzky is affiliated with the following schools:

Jorge Plutzky's Academic­Influence.com Rankings

Jorge Plutzky's Degrees

Why Is Jorge Plutzky Influential?

Jorge Plutzky's Published Works

Published Works

What Schools Are Affiliated With Jorge Plutzky?

Jorge Plutzky's AcademicInfluence.com Rankings